Bristol Myers Squibb Receives European Commission Approval of Sotyktu (deucravacitinib), a Once-Daily Oral Treatment for Adults With Moderate-to-Severe Plaque PsoriasisBusiness Wire • 03/28/23
Evotec and Bristol Myers Squibb Extend and Expand Strategic Neurodegeneration PartnershipAccesswire • 03/28/23
CHARM Therapeutics Announces Collaboration with Bristol Myers Squibb to Enable and Accelerate Small Molecule Drug Discovery ProgramsBusiness Wire • 03/20/23
Got $5,000? These 2 High-Yielding Dividend Stocks Are Near Their 52-Week LowsThe Motley Fool • 03/16/23
Bristol Myers Squibb Announces Progress Toward Long-Term Inclusion & Diversity Goals and Health Equity CommitmentsBusiness Wire • 03/15/23
Should Investors Buy Bristol Myers or CVS Stock Near 52-week Lows?Zacks Investment Research • 03/11/23
Bristol Myers Squibb to Report Results for First Quarter 2023 on April 27, 2023Business Wire • 03/09/23
Bristol-Myers Squibb Company (BMY) Presents at Cowen 43rd Annual Healthcare Conference (Transcript)Seeking Alpha • 03/07/23
Viz.ai Announces Agreement with Bristol Myers Squibb to Enable Earlier Detection and Management of Suspected Hypertrophic Cardiomyopathy (HCM)Business Wire • 03/03/23
Bristol Myers Squibb Receives European Commission Approval of Reblozyl® (luspatercept) for Anemia in Adult Patients with Non-Transfusion-Dependent Beta ThalassemiaBusiness Wire • 03/03/23
The Bristol Myers Squibb-Janssen Collaboration Launches Pivotal Phase 3 Librexia Clinical Trial Program Evaluating Milvexian, an Investigational Oral Factor XIa InhibitorBusiness Wire • 03/02/23
Bristol Myers Squibb to Participate in Cowen's 43rd Annual Health Care ConferenceBusiness Wire • 02/28/23
Bristol Myers Squibb to Present Data Supporting its Cardiovascular Portfolio at the American College of Cardiology Annual Scientific Session Together With World Congress of CardiologyBusiness Wire • 02/27/23